Bo Lu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11514940/publications.pdf

Version: 2024-02-01

		81900	46799
93 papers	14,272 citations	39 h-index	89 g-index

93 all docs	93 docs citations	93 times ranked	27278 citing authors

#	Article	IF	Citations
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
2	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	9.1	3,122
3	Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy, 2008, 4, 151-175.	9.1	2,064
4	Inhibition of Mammalian Target of Rapamycin or Apoptotic Pathway Induces Autophagy and Radiosensitizes PTEN Null Prostate Cancer Cells. Cancer Research, 2006, 66, 10040-10047.	0.9	321
5	Inhibition of Poly(ADP-Ribose) Polymerase Enhances Cell Death and Improves Tumor Growth Delay in Irradiated Lung Cancer Models. Clinical Cancer Research, 2007, 13, 3033-3042.	7.0	257
6	Enhanced radiation damage of tumor vasculature by mTOR inhibitors. Oncogene, 2005, 24, 5414-5422.	5.9	182
7	Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer. Molecular Cancer Therapeutics, 2006, 5, 1183-1189.	4.1	166
8	Autophagy for Cancer Therapy through Inhibition of Pro-apoptotic Proteins and Mammalian Target of Rapamycin Signaling. Journal of Biological Chemistry, 2006, 281, 36883-36890.	3.4	162
9	Autophagy upregulation by inhibitors of caspase-3 and mTOR enhances radiotherapy in a mouse model of lung cancer. Autophagy, 2008, 4, 659-668.	9.1	162
10	XIAP and survivin as therapeutic targets for radiation sensitization in preclinical models of lung cancer. Oncogene, 2004, 23, 7047-7052.	5.9	160
11	Targeting brain metastases in ALK-rearranged non-small-cell lung cancer. Lancet Oncology, The, 2015, 16, e510-e521.	10.7	160
12	Survivin As a Therapeutic Target for Radiation Sensitization in Lung Cancer. Cancer Research, 2004, 64, 2840-2845.	0.9	146
13	Switch Between Apoptosis and Autophagy: Radiation-Induced Endoplasmic Reticulum Stress?. Cell Cycle, 2007, 6, 793-798.	2.6	134
14	Autophagy signaling in cancer and its potential as novel target to improve anticancer therapy. Drug Resistance Updates, 2007, 10, 135-143.	14.4	113
15	Combined Bcl-2/Mammalian Target of Rapamycin Inhibition Leads to Enhanced Radiosensitization via Induction of Apoptosis and Autophagy in Nonâ€“Small Cell Lung Tumor Xenograft Model. Clinical Cancer Research, 2009, 15, 6096-6105.	7.0	108
16	Progress in the unraveling of the endoplasmic reticulum stress/autophagy pathway and cancer: Implications for future therapeutic approaches. Drug Resistance Updates, 2010, 13, 79-86.	14.4	100
17	Blockade of Tumor-Expressed PD-1 promotes lung cancer growth. OncoImmunology, 2018, 7, e1408747.	4.6	99
18	Nuclear survivin predicts recurrence and poor survival in patients with resected nonsmall cell lung carcinoma. Cancer, 2005, 103, 1685-1692.	4.1	92

#	Article	IF	Citations
19	Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Nonâ€“Small Cell Lung Cancers In Vitro and In Vivo. Clinical Cancer Research, 2016, 22, 122-133.	7.0	83
20	Targeting Myeloid-derived Suppressor Cells and Programmed Death Ligand 1 Confers Therapeutic Advantage of Ablative Hypofractionated Radiation Therapy Compared With Conventional Fractionated Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2018, 101, 74-87.	0.8	82
21	Regulated cell death pathways: New twists in modulation of BCL2 family function. Molecular Cancer Therapeutics, 2009, 8, 1421-1429.	4.1	79
22	Impact of inhomogeneity corrections on dose coverage in the treatment of lung cancer using stereotactic body radiation therapy. Medical Physics, 2007, 34, 2985-2994.	3.0	78
23	Crosstalk Between Bak/Bax and mTOR Signaling Regulates Radiation-Induced Autophagy. Autophagy, 2007, 3, 142-144.	9.1	77
24	PD-1 Modulates Radiation-Induced Cardiac Toxicity through Cytotoxic T Lymphocytes. Journal of Thoracic Oncology, 2018, 13, 510-520.	1.1	77
25	Synergy between phosphatidylinositol 3-kinase/Akt pathway and Bcl-xL in the control of apoptosis in adenocarcinoma cells of the lung. Molecular Cancer Therapeutics, 2009, 8, 101-109.	4.1	66
26	Combining Radiation and Immune Checkpoint Blockade in the Treatment of Head and Neck Squamous Cell Carcinoma. Frontiers in Oncology, 2019, 9, 122.	2.8	63
27	HSP90 Inhibitors: Multi-Targeted Antitumor Effects and Novel Combinatorial Therapeutic Approaches in Cancer Therapy. Current Medicinal Chemistry, 2009, 16, 3081-3092.	2.4	60
28	IGFBP3 Modulates Lung Tumorigenesis and Cell Growth through IGF1 Signaling. Molecular Cancer Research, 2017, 15, 896-904.	3.4	56
29	ALK Inhibitor PF02341066 (Crizotinib) Increases Sensitivity to Radiation in Nonâ€“Small Cell Lung Cancer Expressing EML4-ALK. Molecular Cancer Therapeutics, 2013, 12, 696-704.	4.1	55
30	Addition of Metformin to Concurrent Chemoradiation in Patients With Locally Advanced Nonâ€“Small Cell Lung Cancer. JAMA Oncology, 2021, 7, 1324.	7.1	53
31	Inhibition of JAK2 Signaling by TG101209 Enhances Radiotherapy in Lung Cancer Models. Journal of Thoracic Oncology, 2011, 6, 699-706.	1.1	52
32	Inhibition of signal transducer and activator of transcription 3 activity results in down-regulation of Survivin following irradiation. Molecular Cancer Therapeutics, 2006, 5, 2659-2665.	4.1	49
33	Treatment Design and Rationale for a Randomized Trial of Cisplatin and Etoposide Plus Thoracic Radiotherapy Followed by Nivolumab or Placebo for Locally Advanced Nonâ€“Small-Cell Lung Cancer (RTOG 3505). Clinical Lung Cancer, 2017, 18, 333-339.	2.6	47
34	Deep-inspiration breath-hold kilovoltage cone-beam CT for setup of stereotactic body radiation therapy for lung tumors: Initial experience. Lung Cancer, 2007, 56, 77-88.	2.0	45
35	M867, a Novel Selective Inhibitor of Caspase-3 Enhances Cell Death and Extends Tumor Growth Delay in Irradiated Lung Cancer Models. PLoS ONE, 2008, 3, e2275.	2.5	43
36	Cytoplasmic Clusterin Expression Is Associated with Longer Survival in Patients with Resected Nonâ€“Small Cell Lung Cancer. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 1845-1851.	2.5	41

#	Article	IF	Citations
37	Radiosensitization of solid tumors by Z-VAD, a pan-caspase inhibitor. Molecular Cancer Therapeutics, 2009, 8, 1270-1279.	4.1	41
38	AT-101, a Pan-Bcl-2 Inhibitor, Leads to Radiosensitization of Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2010, 5, 680-687.	1.1	40
39	Opportunities and Challenges in the Era of Molecularly Targeted Agents and Radiation Therapy. Journal of the National Cancer Institute, 2013, 105, 686-693.	6.3	40
40	NVP-BEZ-235 enhances radiosensitization via blockade of the PI3K/mTOR pathway in cisplatin-resistant non-small cell lung carcinoma.. Genes and Cancer, 2014, 5, 293-302.	1.9	40
41	Inhibition of Survivin and Aurora B Kinase Sensitizes Mesothelioma Cells by Enhancing Mitotic Arrests. International Journal of Radiation Oncology Biology Physics, 2007, 67, 1519-1525.	0.8	34
42	Molecular Profiling to Optimize Treatment in Non-Small Cell Lung Cancer: A Review of Potential Molecular Targets for Radiation Therapy by the Translational Research Program of the Radiation Therapy Oncology Group. International Journal of Radiation Oncology Biology Physics, 2012, 83, e453-e464.	0.8	34
43	BV6, an IAP Antagonist, Activates Apoptosis and Enhances Radiosensitization of Non-small Cell Lung Carcinoma In Vitro. Journal of Thoracic Oncology, 2011, 6, 1801-1809.	1.1	33
44	Clusterin as a therapeutic target for radiation sensitization in a lung cancer model. International Journal of Radiation Oncology Biology Physics, 2005, 63, 1228-1236.	0.8	32
45	Beyond Concurrent Chemoradiation: The Emerging Role of PD-1/PD-L1 Inhibitors in Stage III Lung Cancer. Clinical Cancer Research, 2018, 24, 1271-1276.	7.0	32
46	Terameprocol (Tetra-O-Methyl Nordihydroguaiaretic Acid), an Inhibitor of Sp1-Mediated Survivin Transcription, Induces Radiosensitization in Non-small Cell Lung Carcinoma. Journal of Thoracic Oncology, 2011, 6, 8-14.	1.1	30
47	NBTXR3 Radiotherapy-Activated Functionalized Hafnium Oxide Nanoparticles Show Efficient Antitumor Effects Across a Large Panel of Human Cancer Models. International Journal of Nanomedicine, 2021, Volume 16, 2761-2773.	6.7	30
48	The Role of mTOR Inhibition in Augmenting Radiation Induced Autophagy. Technology in Cancer Research and Treatment, 2007, 6, 443-447.	1.9	29
49	Decreased Survival After Combining Thoracic Irradiation and an Anti-PD-1 Antibody Correlated With Increased T-cell Infiltration Into Cardiac and Lung Tissues. International Journal of Radiation Oncology Biology Physics, 2017, 99, 1129-1136.	0.8	27
50	ALDH7A1 expression is associated with recurrence in patients with surgically resected non-small-cell lung carcinoma. Future Oncology, 2013, 9, 737-745.	2.4	25
51	SMAC Mimetic Debio 1143 and Ablative Radiation Therapy Synergize to Enhance Antitumor Immunity against Lung Cancer. Clinical Cancer Research, 2019, 25, 1113-1124.	7.0	25
52	Broad spectrum receptor tyrosine kinase inhibitor, SU6668, sensitizes radiation via targeting survival pathway of vascular endothelium. International Journal of Radiation Oncology Biology Physics, 2004, 58, 844-850.	0.8	24
53	Synergistic effect of immunotherapy and radiotherapy in non-small cell lung cancer: current clinical trials and prospective challenges. Precision Clinical Medicine, 2019, 2, 57-70.	3.3	24
54	Molecular markers to predict clinical outcome and radiation induced toxicity in lung cancer. Journal of Thoracic Disease, 2014, 6, 387-98.	1.4	23

#	Article	IF	Citations
55	Chapter 14 Autophagy in Lung Cancer. Methods in Enzymology, 2009, 453, 287-304.	1.0	22
56	The Zinc Ionophore PCI-5002 Radiosensitizes Non-small Cell Lung Cancer Cells by Enhancing Autophagic Cell Death. Journal of Thoracic Oncology, 2011, 6, 1542-1552.	1.1	22
57	Low Temperature Induced Synthesis of TiN Nanocrystals. Inorganic Chemistry, 2004, 43, 3558-3560.	4.0	21
58	Immune biomarkers of treatment failure for a patient on a phase I clinical trial of pembrolizumab plus radiotherapy. Journal of Hematology and Oncology, 2016, 9, 96.	17.0	21
59	The EGFR Polymorphism rs884419 is Associated With Freedom From Recurrence in Patients With Resected Prostate Cancer. Journal of Urology, 2010, 183, 2062-2069.	0.4	20
60	The use of antisense oligonucleotides in evaluating survivin as a therapeutic target for radiation sensitization in lung cancer. Biological Procedures Online, 2004, 6, 250-256.	2.9	16
61	The Use of Tyrosine Kinase Inhibitors in Modifying the Response of Tumor Microvasculature to Radiotherapy. Technology in Cancer Research and Treatment, 2005, 4, 691-698.	1.9	16
62	A Novel Bioluminescence Orthotopic Mouse Model for Advanced Lung Cancer. Radiation Research, 2011, 176, 486-493.	1.5	15
63	The Matrix Metalloproteinase-7 Polymorphism Rs10895304 Is Associated With Increased Recurrence Risk in Patients With Clinically Localized Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 79, 1330-1335.	0.8	14
64	Evaluation of Elekta 4D cone beam CT-based automatic image registration for radiation treatment of lung cancer. British Journal of Radiology, 2015, 88, 20140620.	2.2	14
65	Stereotactic Body Radiation Therapy Delivery inÂaÂGenetically Engineered Mouse Model ofÂLungÂCancer. International Journal of Radiation Oncology Biology Physics, 2016, 96, 529-537.	0.8	14
66	Biodistribution and Pharmacokinetics Study of siRNA-loaded Anti-NTSR1-mAb-functionalized Novel Hybrid Nanoparticles in a Metastatic Orthotopic Murine Lung Cancer Model. Molecular Therapy - Nucleic Acids, 2016, 5, e282.	5.1	14
67	siRNA-Encapsulated Hybrid Nanoparticles Target Mutant K-ras and Inhibit Metastatic Tumor Burden in a Mouse Model of Lung Cancer. Molecular Therapy - Nucleic Acids, 2017, 6, 259-268.	5.1	14
68	The Use of Gene Therapy in Cancer Research and Treatment. Technology in Cancer Research and Treatment, 2004, 3, 479-490.	1.9	13
69	Comparison of Online 6 Degree-of-Freedom Image Registration of Varian TrueBeam Cone-Beam CT and BrainLab ExacTrac X-Ray for Intracranial Radiosurgery. Technology in Cancer Research and Treatment, 2017, 16, 339-343.	1.9	11
70	Murine double minute 2 as a therapeutic target for radiation sensitization of lung cancer. Molecular Cancer Therapeutics, 2005, 4, 1137-1145.	4.1	10
71	ATM polymorphism IVS62+60G>A is not associated with disease aggressiveness in prostate cancer. Urology, 2006, 67, 1320-1323.	1.0	10
72	No evidence for association of the MDM2-309 T/G promoter polymorphism with prostate cancer outcomes. Urologic Oncology: Seminars and Original Investigations, 2011, 29, 319-323.	1.6	10

#	Article	IF	Citations
73	Debio 1143, an antagonist of multiple inhibitor-of-apoptosis proteins, activates apoptosis and enhances radiosensitization of non-small cell lung cancer cells in vitro. American Journal of Cancer Research, 2014, 4, 943-51.	1.4	9
74	Disparity in age at lung cancer diagnosis between current and former smokers. Journal of Cancer Research and Clinical Oncology, 2019, 145, 1243-1251.	2.5	7
75	Randomized phase III trial of concurrent chemoradiation followed by nivolumab or placebo for locally advanced non-small cell lung cancer (NSCLC) (RTOG 3505).. Journal of Clinical Oncology, 2017, 35, TPS8579-TPS8579.	1.6	7
76	BH3 mimetic ABT-737 sensitizes colorectal cancer cells to ixazomib through MCL-1 downregulation and autophagy inhibition. American Journal of Cancer Research, 2016, 6, 1345-57.	1.4	7
77	Utility of stereotactic ablative radiotherapy/stereotactic body radiation therapy in the setting of oligometastatic non-small cell lung cancer. Journal of Thoracic Disease, 2018, 10, 657-660.	1.4	6
78	A Pilot Study of Radiation Therapy in Combination With Pembrolizumab in Patients With Metastatic Renal Cell Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 82-86.	1.3	5
79	Nitrilase 1 modulates lung tumor progression in vitro and in vivo. Oncotarget, 2016, 7, 21381-21392.	1.8	5
80	Impact of Sarcopenia on Survival in Patients With Early-Stage Lung Cancer Treated With Stereotactic Body Radiation Therapy. Cureus, 2020, 12, e10712.	0.5	5
81	Assessment of M867, a selective caspase-3 inhibitor, in an orthotopic mouse model for non-small cell lung carcinoma. American Journal of Cancer Research, 2014, 4, 161-71.	1.4	5
82	E-cadherin promoter polymorphisms are not associated with the aggressiveness of prostate cancer in Caucasian patients. Urologic Oncology: Seminars and Original Investigations, 2006, 24, 496-502.	1.6	4
83	Cancer Stem Cells. Journal of Oncology, 2011, 2011, 1-1.	1.3	4
84	Stereotactic body radiation therapy (SBRT) for patients with stage I non-small cell lung cancer is applicable to more tumors than sublobar resection. Journal of Thoracic Disease, 2021, 13, 1576-1583.	1.4	3
85	A Novel Radiation-Induced p53 Mutation Is Not Implicated in Radiation Resistance via a Dominant-Negative Effect. PLoS ONE, 2014, 9, e87492.	2.5	3
86	Lung cancer screening: not all nodules are created equal. Journal of Thoracic Disease, 2016, 8, E1257-E1259.	1.4	2
87	Nivolumab plus cisplatin/pemetrexed or cisplatin/gemcitabine as induction in resectable NSCLC.. Journal of Clinical Oncology, 2018, 36, TPS8582-TPS8582.	1.6	2
88	An exploratory study to investigate the immunomodulatory activity of radiation therapy in combination with pembrolizumab in patients with renal cell cancer.. Journal of Clinical Oncology, 2017, 35, e16058-e16058.	1.6	2
89	The incidence of atrial fibrillation shortly following radiation therapy in patients with lung cancer: A population-based study.. Journal of Clinical Oncology, 2022, 40, e18796-e18796.	1.6	1
90	Systemic therapy for echinoderm microtubule-associated protein-like 4 anaplastic lymphoma kinase non-small cell lung cancer brain metastases. Journal of Thoracic Disease, 2016, 8, E1028-E1031.	1.4	0

#	Article	IF	Citations
91	Neoadjuvant PD-1 blockade in non-small cell lung cancer: what else do we need to do?. Journal of Thoracic Disease, 2018, 10, S3162-S3165.	1.4	0
92	Proposal of organ-specific subdivision of M component and staging system for metastatic pulmonary neuroendocrine tumor. Lung Cancer, 2020, 148, 86-93.	2.0	0
93	Predicting overall survival for patients with periampullary carcinoma.. Journal of Clinical Oncology, 2015, 33, 376-376.	1.6	0